Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 11/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | RGS12 | O14924 | 2/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3511018 | 1.00 | HSPB1 (0.49) | HSPB1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL3510643 | 0.91 | HSPB1 (0.55) | HSPB1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL3510639 | 0.91 | HSPB1 (0.55) | HSPB1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL3510993 | 0.84 | KMT2A (0.43) | MAPTSMN1; SMN2POLBLMNAMEN1 | |
| SCHEMBL2450636 | 0.83 | HSPB1 (0.53) | HSPB1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL2450640 | 0.83 | HSPB1 (0.53) | HSPB1MAPTSMN1; SMN2LMNAHTT | |
| SCHEMBL3510832 | 0.81 | HSPB1 (0.52) | HSPB1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL1260299 | 0.81 | HSPB1 (0.60) | HSPB1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL1260304 | 0.81 | HSPB1 (0.60) | HSPB1MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL3510827 | 0.81 | HSPB1 (0.52) | HSPB1MAPTSMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | HSPB1 3348/4885MAPT 4439/4885SMN1; SMN2 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.